Importantly, we found that higher AP4 expression levels were correlated with shorter biochemical disease-free survival (bDFS) in patients with PCa than lower AP4 expression levels (HR, 2.070, 95% CI, 1.153-3.171; P<0.05). Here, TFAP4 is linked to posterior cortical atrophy.